FDA Gives Abbvie’s Qulipta the Nod for Chronic Migraine Prevention

April 19, 2023

Woman sitting at desk holding her head in one hand while grimacing in pain.

The US Food and Drug Administration (FDA) approved the use of Abbvie’s Quilipta as a preventive treatment for chronic migraines. This approval gives AbbVie a leg up on Pfizer, whose migraine drug Nurtec ODT is not officially approved for chronic migraines. The decision was made based on data from a phase 3 trial that found the drug significantly reduced migraine day for patients.

According to Zoey Becker, “Trial investigators also sought to determine the proportion of patients who achieved at least a 50% reduction in mean monthly migraine days. In both the U.S.- and EU-focused patient populations, that proportion came out to 41% of patients in the 60-mg group and 42.7% in the 30-mg group, compared with around 26% for placebo.”

To read more, click here.

(Source: Fierce Pharma, April 18th, 2023)

Share This Story!